In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...
MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a $27.425 million first closing of its Series A ...
A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how ...
Verastem Oncology said it has dosed its first patient in a trial of its investigational cancer medication as a treatment for KRAS G12D-mutated metastatic pancreatic cancer. The biopharmaceutical ...
Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.
Enhancing Readability of Lay Abstracts and Summaries for Urologic Oncology Literature Using Generative Artificial Intelligence: BRIDGE-AI 6 Randomized Controlled Trial We trained and tested ML systems ...
A massive 10-year population study reveals that neovascular age-related macular degeneration (nAMD) is linked to an increased ...
Short-Term Surgical Mission in Sub-Saharan Country, Experience of a Breast-Dedicated Team: Reviewing the Past and Stepping Toward the Last Mission Rapidly expanding systemic treatment options, ...
Share on Pinterest Scientists are looking at the effects of the keto diet on cancer therapies. Dulin/Getty Images A ketogenic diet can interact with certain cancer therapies to block the development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results